Showing results (71-80 of 130) with videos related to
Sort By:
Pageof 13
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 9, 2005
Rejection after simultaneous pancreas-kidney transplantationHelmut Arbogast, Jacques Malaise, Wolf-Dieter Illner, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 8, 2005
A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimusE Steve Woodle, Flavio Vincenti, Marc I Lorber, et al.Journal of the American Society of Nephrology : JASN|August 8, 2025
Dysregulated Bone Marrow Contributes to Glomerular Injury through Soluble FactorsRyan Spear, Alexis P Jimenez-Uribe, Yanxia Cao, et al.Transplantation|July 9, 2004
Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimusChristoph D Dieterle, Susanne Schmauss, Martin Veitenhansl, et al.British Journal of Clinical Pharmacology|June 9, 2007
Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patientsMark D Pescovitz, Flavio Vincenti, Marquis Hart, et al.Clinical Journal of the American Society of Nephrology : CJASN|September 17, 2011
Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetesLionel Rostaing, Hans H Neumayer, Rafael Reyes-Acevedo, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 20, 2003
Prevalence and management of anemia in renal transplant recipients: a European surveyYves Vanrenterghem, Claudio Ponticelli, José Maria Morales, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 28, 2016
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized TrialJosep M Grinyó, Maria Del Carmen Rial, Josefina Alberu, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 31, 2020
Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipientsAllan D Kirk, Andrew B Adams, Antoine Durrbach, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|September 22, 2012
Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipientsQizhi Tang, Joey Leung, Kristin Melli, et al.Pageof 13